Premium
Replacing chemotherapy with arsenic trioxide for the treatment of acute promyelocytic leukemia in the frontline setting: Is it cost‐effective?
Author(s) -
Yilmaz Umut,
Eskazan Ahmet Emre
Publication year - 2020
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.32608
Subject(s) - arsenic trioxide , acute promyelocytic leukemia , medicine , arsenic , chemotherapy , leukemia , intensive care medicine , oncology , retinoic acid , biochemistry , materials science , chemistry , metallurgy , gene
Arsenic trioxide (ATO) is highly effective for the treatment of patients with acute promyelocytic leukemia (APL). In their study, Chen et al analyze the financial impact of the use of ATO in the upfront treatment setting for patients with APL in China and report it to be cost‐effective, a finding that is consistent with previous studies conducted in the United States and Canada.